(722) Angiotensin II Use in Cardiogenic Shock Patients Supported by Temporary Mechanical Circulatory Support

PurposeThe use of Angiotensin II (ANGII), the most potent endogenous vasopressor, has not been studied in patients with cardiogenic shock on temporary mechanical circulatory support (tMCS). We aimed to evaluate hemodynamic response ANGII adult tMCS and further describe patient characteristics its efficacy.MethodsCardiogenic who were supported by (IABP, Impella, VA-ECMO) received included study. Patients requiring durable MCS or right ventricular excluded. Clinical, pharmacological, hemodynamic, echocardiographic obtained at time initiation ANGII. A positive was considered if mean arterial pressure increased 10mmHg there a decrease NE equivalent dose, 30 minutes after initiation.ResultsForty met inclusion criteria, clinical are summarized Table 1. Mean age 55.7±16.8 years, 72.5% male. Twenty-three (57.5%) ECMO, 12 (30%) impella, 11 (27.5%) IABP initiation. In addition, 18 (45%) renal replacement therapy. The SOFA score 9.5±3.3 ANG Twenty-six (65%) categorized as responders their shown table1. There no significance between non-responders. mortality rate 90 days for 71.4% 69.2% (p=1) non-responders responders, respectively.ConclusionIn tMCS, administration associated significant other vasopressor medications 65% patients. Response day survival. efficacy. Cardiogenic Forty respectively.